For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$48.77
Thesis
Novo Nordisk markets the semaglutide products Ozempic and Wegovy for type 2 diabetes and obesity. As a diversified company, its incretin franchise sits alongside a broader diabetes and metabolic portfolio.
Catalysts
- Semaglutide supply and manufacturing expansion
- Next-generation incretin clinical readouts
- Label expansions for Ozempic and Wegovy
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jul 24OtherClinicalTrials.gov
Phase 3 trial NCT07011667 for CagriSema in long-term obesity weight loss updated to ACTIVE_NOT_RECRUITING.
- Jul 23Trial initiationClinicalTrials.gov
Phase 3 CLEOPATTRA trial (NCT07207811) initiated for Coramitug in ATTR amyloidosis heart failure; recruiting status per 2026-07-23 update.
- Jul 22Trial initiationClinicalTrials.gov
Novo Nordisk Phase 3 trial NCT07720271 (Zenagamtide tablets, excess body weight) status NOT_YET_RECRUITING.
- Jul 22Trial readoutClinicalTrials.gov
Phase 2 trial NCT05405114 of NDec in sickle cell disease completed (status update 2026-07-22).
- Jul 21Trial initiationClinicalTrials.gov
Novo Nordisk Phase 3 trial NCT07668401 (Zenagamtide, Asia weight loss) status NOT_YET_RECRUITING as of 2026-07-21.
- Jul 17Trial initiationClinicalTrials.gov
Novo Nordisk initiates Phase 3 trial NCT07253285 evaluating Cagrilintide and CagriSema in children and adolescents with excess body weight; status recruiting.
- Jul 17Trial readoutClinicalTrials.gov
Phase 3 REDEFINE 3 trial (NCT05669755) of CagriSema in cardiovascular disease updated to ACTIVE_NOT_RECRUITING status.
- Jul 15Trial initiationClinicalTrials.gov
Novo Nordisk initiates Phase 3 trial NCT07567001 of NNC0487-0111 vs placebo in heart failure with obesity; status recruiting.